Alida Biosciences Secures Series A Funding

By Author: Ben Gross
Total Articles: 460
Comment this article

Introducing Breakthrough Solutions for Cutting-Edge Research

We are thrilled to announce that Alida Biosciences has successfully concluded a Series A funding round, raising an impressive $7.5 million. This funding round was led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners. In addition to this, we have also received two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute. This financial support will enable us to continue our groundbreaking work in epigenomic research.

But that's not all! We are excited to unveil the Early Access launch of two game-changing products: the EpiPlex™ RNA Library Prep Kit and the EpiScout™ Analysis Suite. These innovative tools provide a comprehensive solution for multiplexed epitranscriptomic analysis of clinical research RNA samples, even when input amounts are limited. With unprecedented sensitivity and accuracy, researchers can now delve deeper into the world of RNA modifications.

The EpiPlex RNA Library Prep Kit is designed to revolutionize epitranscriptomic research. By integrating a streamlined ...
... assay workflow with an intuitive bioinformatics platform, this kit enables high-sensitivity analysis of RNA modifications. The epitranscriptome, with its diverse array of naturally occurring RNA modifications, plays a crucial role in regulating RNA biology. From RNA-protein interactions to intracellular trafficking, understanding these modifications is key to unlocking the mysteries of RNA.

Unlike traditional methods that can only detect a single type of modification per assay and require large amounts of RNA, the EpiPlex kit overcomes these limitations. It utilizes non-antibody binders (NABs) that exhibit high affinity and minimal off-target binding. This results in superior reproducibility, sensitivity, and accuracy, even with low RNA inputs. Researchers can now explore the world of RNA modifications with confidence, knowing that they have a reliable and efficient tool at their disposal.

The Early Access launch of these products comes after several beta customer experiences, and we are thrilled to report that customers have expressed high satisfaction with the improved workflow and exceptional data quality. We are proud to be at the forefront of epigenomic research, providing researchers with the tools they need to make groundbreaking discoveries.

Join us on this exciting journey as we continue to push the boundaries of scientific exploration and pave the way for a better understanding of epitranscriptomics. Together, we can unlock the secrets hidden within RNA and revolutionize the field of molecular biology.

More Information : https://www.techdogs.com/tech-news/pr-newswire/alida-biosciences-announces-series-a-funding-and-early-access-launch-of-innovative-products-for-epitranscriptomic-research